|SYSTEM ORGAN CLASS||FREQUENCY||ADVERSE REACTION|
|Infections and infestations||≥1% to <10%||Conjunctivitis, oral herpes|
|Blood and lymphatic system disorders||≥1% to <10%||Eosinophilia|
|Immune system disorders||<0.01%||Serum sickness/serum sickness-like reactions|
|Not known||Anaphylactic reaction†, Angiodema†|
|Nervous system disorders||≥1% to <10%||Headache|
|Eye disorders||≥1% to <10%||Conjunctivitis allergic, eye pruritus, blepharitis|
|≥0.1% to 1%||Keratitis, Ulcerative keratitis|
|Musculoskeletal and connective tissue disorders||Not known||Arthralgia†|
|General disorders and administration site conditions||Not known||Injection site reactions|
*Pooled data from placebo-controlled monotherapy clinical studies and placebo-controlled concomitant therapy with TCS study; patients exposed
to DUPIXENT 300 mg QW or 300 mg Q2W.1
†From post-marketing reporting.
AD, atopic dermatitis; OLE, open label extension; QW, once weekly; Q2W, once every two weeks; TCS, topical corticosteroids.